Ardena has appointed Ariane de Ganck as Chief Scientific Officer, reinforcing its focus on scientific excellence across its integrated CDMO and bioanalytical services.
Ariane has held several senior roles at Ardena, including leadership of the Drug Product division since 2022 and, more recently, serving as Chief Commercial Officer.
Since joining the company in 2019, she has overseen drug product operations, led the acquisition and integration of the Pamplona site and supported Ardena’s expansion into aseptic fill and finish services.
In her new role, Ariane will lead Science & Technology, Project Management and CMC Regulatory Affairs.
Jeremie Trochu, CEO of Ardena, said: “Ariane’s track record across scientific, operational and commercial leadership roles makes her exceptionally well suited to this position.”
He said: “For customers developing complex molecules, integrated scientific input across disciplines is essential.
“As Chief Scientific Officer, Ariane will help ensure Ardena’s expertise is applied consistently across complex development programmes, supporting our customers as they advance therapies with the potential to improve patients’ lives.”
